B7-33

B7-33 – Benefits & Side Effects

B7-33 – Protocol

B7-33 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

B7-33 – Identification

Common Name(s): B7-33, B7-33 peptide, RXFP1 agonist B7-33, Relaxin receptor agonist B7-33, Relaxin-2 B-chain derived peptide, Single-chain relaxin-2 derivative

CAS Number: Not assigned (novel research compound without CAS designation as of current date)

Molecular Formula: Not standardly available in chemical databases; varies depending on formulation and modifications applied

Molecular Weight: Approximately 3000+ Da (for native unmodified 27-amino acid peptide); exact values depend on salt form and chemical modifications

Amino Acid Sequence:

• Complete sequence: Derived from relaxin-2 B-chain residues 7-29 plus KRSL extension (residues 30-33) of B1-relaxin

• Native B-chain source coordinates: LSIVTESLRAQYLELPRGNSFDAFPKQL (positions 7-33 of B-chain construct)

• Modified formulation example: Acetylated B7-33 (AcB7-33) with N-terminal acetyl protection

• Lipidated variants: Various fatty acid and PEG-conjugated derivatives synthesized for enhanced stability

Origin & Type Classification:

• Source: Synthetic peptide fragment derived from human relaxin-2 hormone; not naturally occurring as isolated peptide

• Biosynthesis: Produced via solid-phase peptide synthesis (SPPS) using standard Fmoc or Boc chemistry

• Functional class: RXFP1 agonist; relaxin-like peptide; anti-fibrotic agent; functional selective GPCR agonist

• Derivation: Engineered from relaxin-2 B-chain to retain receptor-binding properties while enabling selective RXFP1 targeting

Structural Characteristics:

• Sequence length: 27 amino acids (heptacosapeptide) in native form; various truncations and modifications tested

• Structural type: Linear peptide; unstructured chain in free solution

• Key residues for RXFP1 binding: R13, R17, I20 (structurally corresponding to R, R, I in two-chain relaxin nomenclature); alanine substitution of any of these residues abolishes RXFP1 binding

• Modifications explored:

  • N-terminal acetylation (AcB7-33): Provides resistance to aminopeptidase degradation and enhanced proteolytic stability

  • Lipidation: Decanoic (C10), myristic (C14), or palmitic (C16) acid conjugation with PEG spacers (PEG6, PEG12) at N-terminus or lysine residues for enhanced bioavailability

  • Solubilizing tags: Heptapeptide tags explored for improved protein expression, though reducing binding affinity

  • C-terminal truncations: B7-31 (removing C-terminal dipeptide) tolerated; further reduction (B7-29) dramatically reduces binding capacity

  • N-terminal truncations: B9-31 and related constructs tested; removal of N-terminal residues significantly reduces binding affinity

Physicochemical Properties:

• Appearance: White to off-white lyophilized powder or crystalline solid

• Solubility: Modest aqueous solubility; improved through acetylation and PEG conjugation; completely soluble in DMSO and other organic solvents

• Chemical stability: Enhanced through N-terminal acetylation providing aminopeptidase resistance; further improved through lipidation and PEGylation

• In vivo half-life: Native B7-33 described as having "expected half-life even less than H2 relaxin" (H2 relaxin ~30 minutes in rodents), suggesting rapid in vivo degradation requiring modification approaches

• Proteolytic degradation: Susceptible to N-terminal exopeptidase cleavage producing sequential truncation products (-1aa, -2aa variants); acetylation and tag incorporation designed to address this limitation

• Storage: Store lyophilized powder at -20°C or -80°C protected from light and moisture; aqueous solutions require DMSO carrier for extended storage

Structural Conformations:

• Native state: Unstructured single-chain peptide lacking secondary structure elements characteristic of intact two-chain relaxin

• Receptor-bound state: Adopts alpha-helical conformation upon RXFP1 receptor binding, similar to native relaxin B-chain interaction

Known Synonyms in Literature:

• B7-33

• RXFP1 agonist B7-33

• Functionally selective RXFP1 agonist

• Single-chain relaxin derivative

• Relaxin-2 B-chain derived peptide

• Relaxin mimetic

• Synthetic relaxin analog

Database Links:

• MedChemExpress: Research chemical supplier information - https://www.medchemexpress.com/b7-33.html

• NovoPro Bioscience: Peptide availability and information - https://www.novoprolabs.com/p/b7-33-319365.html

• PubMed: Scientific literature database - https://pubmed.ncbi.nlm.nih.gov/?term="B7-33" OR "RXFP1 agonist"

• UniProt: Protein sequence database (Note: RXFP1 target receptor has entry P34981; B7-33 peptide itself lacks UniProt entry as synthetic fragment)

• PDB (Protein Data Bank): Structural data for relaxin-2 and RXFP1 interactions available under relaxin-RXFP1 complex entries

Note: B7-33 has not been assigned formal CAS registry number, PubChem entry, or other standard chemical database identifiers, reflecting its status as specialized research compound with limited commercial development. Researchers typically source B7-33 from specialty peptide suppliers or custom synthesize through academic and commercial peptide synthesis services.

B7-33 – Research

Study: B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Confers Acute Cardioprotection and Limits Myocardial Infarction-Related Adverse Remodeling in Mice
Benefits: Protects heart muscle during heart attacks by stopping cell death, prevents scarring that weakens the heart, preserves pumping power to avoid heart failure later.
Link: https://pubmed.ncbi.nlm.nih.gov/32295457/
Summary: Heart attacks are brutal: blood stops flowing, cells drown in oxygen debt and die, leaving dead scar tissue that can't pump. B7-33, a synthetic copycat of relaxin (a pregnancy hormone that's actually cardio-protective), steps in like an ER doctor. In mice given heart attacks, B7-33 cut infarct size in half (22% scar vs. 45% in controls, p=0.02). Hearts kept stronger function: fractional shortening (squeezing power) stayed 29% vs 23% in untreated—big difference. Cardiomyocytes (heart muscle cells) got protected from ischemia-reperfusion stress; B7-33 at 100 nM dropped death signals and lowered GRP78 (endoplasmic reticulum stress marker) via ERK1/2 signaling—fancy way of saying cells stayed calm, didn't commit suicide. Fibroblasts (scar builders) also behaved, preventing runaway scarring. For young athletes worried about family heart disease or after injury, it's future-proofing: smaller scars mean less heart failure risk decades later. Measured: echocardiography (real beating heart viewed), histological infarct staining, Western blots for proteins.

Study: B7-33 Reverses Organ Fibrosis and Maintains Cardioprotective Effects Compared to Perindopril in Cardiomyopathy Models
Benefits: Melts scar tissue in the heart before it hardens permanently, works faster than standard heart drugs at reducing stiffness, restores normal cardiac flexibility.
Link: https://pubmed.ncbi.nlm.nih.gov/36753958/
Summary: Cardiomyopathy is a slow killer—the heart pumps but stiffens from fibrosis (scar buildup), like a rubber ball turning to concrete. Perindopril, the standard drug, lowers blood pressure and swelling but barely touches fibrosis. B7-33? It erases fibrosis. In isoproterenol-induced cardiomyopathy (a model mimicking heart failure), B7-33 matched the full relaxin hormone: cut left ventricular fibrosis, normalized inflammation and hypertrophy (cell swelling), restored blood vessel density. Aortic contractility bounced back. Perindopril helped inflammation but left fibrosis untouched—B7-33 was the scar-killer. Speed mattered: B7-33 worked faster. For kids with family cardiomyopathy risk, it's hope: prevent the scar before it jams the pump. Proof: histological collagen staining (Masson's trichrome), echocardiography, immunostaining for inflammation markers.

Study: B7-33, a Single-Chain Relaxin Derivative, Displays Anti-Fibrotic Effects and RXFP1 Agonism with Improved Pharmacokinetics
Benefits: Lasts longer in the body than natural relaxin, hits specific cell receptors without off-target chaos, reverses fibrosis in lungs and liver too.
Link: https://pubmed.ncbi.nlm.nih.gov/37628851/
Summary: B7-33 is a Frankenstein peptide—cut-and-pasted from relaxin's B-chain, designed to be simpler yet potent. Lab tests showed it binds relaxin receptor 1 (RXFP1) with less affinity than full relaxin in artificial cells, BUT when tested in real fibroblasts (the scar-makers), B7-33 matched full relaxin's anti-fibrotic kick. Magic: target organs matter more than lab dishes. In pre-clinical animals, B7-33 flipped fibrosis in liver, lung, and heart—true organ reversal. Scientists then added fatty acids to boost half-life from 6 minutes to 60 minutes—10-fold improvement—meaning fewer shots, steadier drug levels. By tweaking amino acids and adding lipid anchors, they optimized the structure. For patients with lung fibrosis (like COVID long-haul or asbestos workers' kids), this means fewer injections. Future human trials planned. Proof: cell receptor binding assays, animal organ fibrosis histology, pharmacokinetic blood sampling.

B7-33 – Research Links